Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

The best metric is not weight, but a particularly toxic kind of fat.

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Individuals who lived with obesity as children are less likely to be in work or studying in their mid-20s than their peers, ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

New research presented at the European Congress on Obesity (ECO2025) in Malaga, Spain (11–14 May) reveals that adverse ...

Wearing a weighted vest during a 6-month calorie-restricted weight loss program helped older adults with obesity regain less ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...